Diaceutics PLC announced two enterprise-level, multi-disease data engagements, with two top 10 global pharmaceutical companies. Combined, the contracts will deliver a cumulative value of USD 7 million over a two year period, demonstrating Diaceutics' continued successful transition to a subscription based model and further validating the Group's strategy and platform technology investments to date. Diaceutics will deliver a number of subscription data services to help these global pharmaceutical organizations commercialise their therapeutic treatments more quickly, accurately and efficiently, increasing the uptake by eligible patients and enhancing the organisations' return on R&D investment.